Company Filing History:
Years Active: 2009-2012
Title: Thomas Krieg: Innovator in Vascular Endothelial Growth Factor Research
Introduction
Thomas Krieg is a notable inventor based in Cologne, Germany. He has made significant contributions to the field of vascular biology, particularly through his work on vascular endothelial growth factor (VEGF). With a total of 2 patents, his innovations are paving the way for advancements in medical treatments.
Latest Patents
Thomas Krieg's latest patents focus on the use of proteolysis-resistant active VEGF. The first patent describes a VEGF variant in which the alanine at amino acid position 111 is replaced by proline. Additionally, the arginine at amino acid position 110 may be substituted with another amino acid. This invention also encompasses derivatives of the VEGF, nucleic acids, expression systems, and medicaments. The application of these VEGF mutants is particularly aimed at the treatment of chronic wounds.
Career Highlights
Thomas Krieg is currently associated with Bayer Innovation GmbH, where he continues to push the boundaries of research in his field. His work has garnered attention for its potential impact on therapeutic strategies for chronic wound management.
Collaborations
Throughout his career, Thomas has collaborated with esteemed colleagues such as Sabine Eming and Stephan Sollberg. These partnerships have further enriched his research and innovation efforts.
Conclusion
In summary, Thomas Krieg is a prominent inventor whose work on VEGF has the potential to revolutionize treatments for chronic wounds. His contributions to the field are invaluable and continue to inspire future innovations.